INCY
NASDAQIncyte Corp.
SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological Resarch
Price$124.98+1.94 (+1.58%)
01:30 PM07:45 PM
News · 26 weeks115-79%
2026-03-082026-08-30
Mix6690d
- Insider38(58%)
- Other16(24%)
- SEC Filings7(11%)
- Earnings3(5%)
- Analyst2(3%)
Latest news
25 items- PRIncyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: 21st Annual Wells Fargo Healthcare Conference on Wednesday, September 9, 2026 at 11:00 a.m. EDT Cantor Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 9:45 a.m. EDT Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 at 12:20 p.m. EDT The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless foc
- SECIncyte Corp. filed SEC Form 8-K: Other Events8-K - INCYTE CORP (0000879169) (Filer)
- PRKnight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in BrazilMONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Projec
- INSIDEREVP, Human Resources Basi Ramitpal K covered exercise/tax liability with 504 shares, decreasing direct ownership by 4% to 10,993 units (SEC Form 4) (withholding obligation)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J sold $1,356,174 worth of shares (10,801 units at $125.56), decreasing direct ownership by 6% to 183,200 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- ANALYSTCanaccord Genuity initiated coverage on Incyte with a new price targetCanaccord Genuity initiated coverage of Incyte with a rating of Buy and set a new price target of $152.00
- PRIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Incyte Corporation (NASDAQ:INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company’s common stock and stock option awards to purchase an aggregate of 18,172 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of August 3, 2026, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU vests as to 25% of the shar
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J sold $1,305,422 worth of shares (10,640 units at $122.69), decreasing direct ownership by 5% to 204,804 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mayes Patrick A exercised 2,207 shares at a strike of $106.47 and sold $273,646 worth of shares (2,207 units at $123.99) (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J sold $1,901,794 worth of shares (15,888 units at $119.70), decreasing direct ownership by 7% to 215,444 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mayes Patrick A exercised 45,767 shares at a strike of $78.48 and sold $5,734,376 worth of shares (47,954 units at $119.58), decreasing direct ownership by 3% to 61,441 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- PRNew Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBSMinjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).[1],[2]In the pivotal Phase 3 inMIND clinical trial, patients with R/R FL receiving the Minjuvi combination regimen experienced a significant improvement in progression-free survival, with a 57% reduction in the risk of disease progression, relapse or death, compared with placebo plus lenalidomide and rituximab.[3]Follicular lymphoma is the second most common non-Hodgkin lymphoma (NHL), with
- PROpzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic DermatitisThe European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24, and was well tolerated 1,2,3 Incyte (NASDAQ:INCY) today announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. "The European Commission's approval of Opzelura is an important milestone for adults in Europe living with moderate atopic dermatitis
- SECSEC Form 10-Q filed by Incyte Corp.10-Q - INCYTE CORP (0000879169) (Filer)
- SECIncyte Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INCYTE CORP (0000879169) (Filer)
- PRIncyte Reports Second Quarter 2026 Financial Results and Provides Business UpdatesTotal revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an increase of 38% and 40%, respectively, compared to the second quarter of 2025 Total net sales, excluding the one-time, non-cash benefit for Opzelura® (ruxolitinib) cream related to the CMS settlement,* grew 17% compared to the prior year period Jakafi®/Jakafi XR™ (ruxolitinib) net sales of $817 million, an increase of 7% compared to the same period in 2025 Opzelura net sales of $450 million, an increase of 173% versus the prior year period; excluding the one-time, non-cash benefit,* Opzelura net sales were $204 million, an increase of 24% versus the prior year period Hematology and
- INSIDERSEC Form 4 filed by EVP, Head of Tech. Operations Morrissey Michael James4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Head of Incyte Intl Heeson Lee4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERPrincipal Accounting Officer Tray Thomas was granted 2,834 shares, increasing direct ownership by 15% to 21,699 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERCMO & Head of Late-Stage Dev. Stein Steven H sold $215,348 worth of shares (1,877 units at $114.73) and was granted 9,798 shares, increasing direct ownership by 34% to 30,916 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mayes Patrick A was granted 5,916 shares, increasing direct ownership by 10% to 63,628 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J was granted 13,403 shares, increasing direct ownership by 6% to 231,332 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP, Head of U.S. Commercial Issa Mohamed Khairie sold $125,706 worth of shares (1,093 units at $115.01) and was granted 7,857 shares, increasing direct ownership by 10% to 71,797 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP, Human Resources Basi Ramitpal K was granted 4,991 shares, increasing direct ownership by 77% to 11,497 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP, Chief Strategy Officer Gardner David H was granted 7,395 shares, increasing direct ownership by 78% to 16,824 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
INCY FAQ
6 questionsWhat does Incyte Corp. do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial...Where does INCY stock trade?
Incyte Corp. (INCY) is listed on NASDAQ.What sector and industry is INCY in?
Incyte Corp. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.What are analysts saying about INCY?
Incyte Corp. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-08-20.What companies are similar to INCY?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), CRL (Charles River Laboratories International Inc.), ICLR (ICON plc). Compare INCY side-by-side with any of them on Quantisnow.How can I track INCY on Quantisnow?
Quantisnow aggregates Incyte Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INCY to receive live email and push alerts on every new disclosure.